Original reporting and analysis on the stories shaping biotech.
BioMarin is pulling its $2.9 million hemophilia gene therapy Roctavian from the market after failing to find a single buyer. Combined with Pfizer's identical retreat from its own hemophilia gene therapy, it raises a billion-dollar question: can one-time cures ever make money?
Three completely unrelated viruses independently figured out how to kill bacteria by attacking the same protein. Caltech scientists think this viral trick could unlock an entirely new class of antibiotics against drug-resistant superbugs.
Cambridge researchers engineered self-assembling RNA "nanostars" that build programmable compartments inside bacteria for the first time. The implications for how we manufacture therapeutic proteins could be enormous.
A brand-new biotech just launched with $130 million to target migraines through a completely different pathway than every existing preventive drug. For patients who don't respond to CGRP therapies, Slate Medicines might be building the backup plan they've been waiting for.
Dupixent just landed its ninth FDA approval, this time as the first-ever drug for allergic fungal rhinosinusitis. The trial data is staggering: a 92% reduction in the need for surgery or steroids. For patients stuck in a brutal cycle of repeat sinus surgeries, everything just changed.
Bristol Myers Squibb paid $800 million for a cancer drug from a Chinese biotech nobody was watching. It just hit both survival endpoints in the toughest form of breast cancer, marking the first time a bispecific ADC has pulled off that feat. The $8.4 billion bet is starting to look like a bargain.
The Senate titled its FDA hearing "From Regulator to Roadblock" and brought in biotech CEOs and patient advocates to make the case. With fresh legislation already reshaping orphan drug exclusivity and a $243 billion market at stake, rare disease biotechs are paying very close attention.
A new biotech called Five Discovery wants to give your brain the healing power of psychedelics without the hallucinations. They're not alone in the race, and the science behind it is surprisingly compelling.
AbbVie wired $650 million to Chinese biotech RemeGen for a cancer drug still in phase 2 trials, with the total deal potentially worth $5.6 billion. It's a massive bet that bispecific antibodies will reshape oncology, and AbbVie isn't the only one racing to find out.
Novo Nordisk's Triple G obesity drug just posted nearly 20% weight loss in 24 weeks, adding a metabolic twist that existing drugs don't have. But with Lilly's retatrutide already showing 29% in trials, the real fight is just getting started.
Earendil Labs just signed an $885 million deal with WuXi XDC for linker technology, the unglamorous connector that holds cancer-killing ADCs together. In biotech's hottest arms race, the most valuable weapon might be the glue.
Gilead is spending $7.8 billion to acquire Arcellx and its next-gen CAR-T therapy for multiple myeloma. The secret weapon? A synthetic protein one-third the size of what competitors use, with clinical data that might just be best-in-class.
Novartis paid $12 billion for Avidity Biosciences but left the cardiology programs on the table. Those "leftovers" just launched as Atrium Therapeutics with $270 million and two preclinical heart disease drugs. Sometimes the best biotechs are built from what big pharma didn't want.
Sarepta's Doug Ingram is retiring after a decade of FDA battles, gene therapy breakthroughs, and an 82% stock collapse. His departure, driven partly by his own family's muscular dystrophy diagnosis, leaves behind one of biotech's most complicated legacies.
GSK is paying $950 million in cash for a Canadian startup whose lead drug has never been tested in a single patient with pulmonary hypertension. The science behind the deal, and the market it's chasing, might explain why.
Viatris beat earnings expectations and landed an analyst upgrade, then announced 3,200 job cuts. With at least 18 companies slashing headcount in early 2026, biotech's layoff wave isn't slowing down. It might be the new normal.
Bristol Myers Squibb's $8.4 billion ADC bet just cleared its biggest hurdle yet, hitting both survival endpoints in a Phase 3 trial against one of cancer's most ruthless forms. The full numbers aren't out yet, but what we know so far has major implications for TNBC patients and the red-hot ADC market.
Novo Nordisk just dropped $2.1 billion on a tiny MIT spinout to crack oral biologic delivery for obesity drugs. With Eli Lilly's oral GLP-1 already beating Novo's in head-to-head trials, this might be the most important bet the Danish pharma giant has ever made.
A Japanese chemicals-and-housing conglomerate just dropped $920 million on a German antiviral biotech. It sounds absurd — until you look at what Asahi Kasei has been quietly building for the last 50 years.
Boehringer Ingelheim just dropped $500 million on a preclinical pill from a tiny Oxford biotech, and it's not the only massive immunology deal they've inked lately. The race to replace autoimmune injections with oral therapies is getting very expensive, very fast.
Accent Therapeutics killed its entire DHX9 inhibitor program after safety concerns torpedoed its first-in-human cancer trial. The setback raises tough questions about whether RNA helicases (one of oncology's most tantalizing target families) can ever be safely drugged.
Half of migraine patients don't respond to CGRP drugs, the only biologic game in town. A brand-new startup just launched with $130 million to target a completely different brain pathway, and it could change the treatment map entirely.
Join thousands of biotech professionals who start their day with our free, daily briefing.